Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
- Conditions
- Chronic Lymphocytic Leukemia
- Registration Number
- NCT01081015
- Lead Sponsor
- Celgene
- Brief Summary
The purpose of the Connect™ Chronic Lymphocytic Leukemia (CLL) Disease Registry is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employed in both the community and academic settings.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1494
- Clinical diagnosis with CLL
- Clinical decision made to initiate first-line therapy, second-line therapy or subsequent line of therapy prior to enrollment into the ConnectTM CLL registry, but within 2 months of enrollment
- Age≥18 years
- Willing and able to provide signed informed consent
- Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel
- Participation in a clinical study in which study treatment is blinded
- Patient condition is considered terminal (i.e.<6 months to live)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identify and summarize patterns in therapeutic regimens and patient outcomes up to 8 years The primary objective is to 1) describe practice patterns of first line therapy regimens and subsequent therapeutic strategies in patients initiated on therapy for CLL, as well as initiated on second line and subsequent therapies, in the community and academic setting (2) Provide insight into therapeutic regimens and therapy sequence in clinical practice as they relate to clinical outcomes in patients initiated on first-line, second-line or subsequent therapies for CLL.
- Secondary Outcome Measures
Name Time Method Health Related Quality of Life Measures Related to Therapeutic Regimens up to 8 years Describe the health-related quality of life of patients actively treated for CLL, and to explore the association of HRQoL with therapeutic regimens, sequences and clinical outcomes.
Summarize Effectiveness of Treatment Regimens up to 8 years Describe any differences in effectiveness associated with treatment regimens, including first-line regimens and subsequent therapeutic strategies in patients actively treated for CLL
Trial Locations
- Locations (165)
New Hope Cancer & Research Institute
🇺🇸Pomona, California, United States
Medical Specialists of the Palm Beaches
🇺🇸Atlantis, Florida, United States
University Cancer Institute
🇺🇸Boynton Beach, Florida, United States
Thomas Niederman, MD
🇺🇸Boynton Beach, Florida, United States
Pasco Hernando Oncology Associates (Kumar)
🇺🇸New Port Richey, Florida, United States
Phoebe Putney Memorial Hospital
🇺🇸Albany, Georgia, United States
Peachtree Hematology-Oncology Consultants
🇺🇸Atlanta, Georgia, United States
Georgia Cancer Specialists
🇺🇸Atlanta, Georgia, United States
US Oncology - Dublin Hematology & Oncology
🇺🇸Dublin, Georgia, United States
Straub Clinic and Hospital
🇺🇸Honolulu, Hawaii, United States
Scroll for more (155 remaining)New Hope Cancer & Research Institute🇺🇸Pomona, California, United States